Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Athira Pharma, Inc. (ATHA)  
$0.00 0.00 (0.00%) as of 4:30 Tue 11/30


Download
   
Exchange: N/A
Security Type: N/A
Shares Out: 30,820,000
Market Cap: N/A
Last Volume: 0 Avg Vol: 0
52 Week Range: $ - $
Level I Sector: N/A
Level II Sector: N/A
Level III Sector: N/A

Member Indexes:
   

Rankings:
     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  -
Guru Rank Value     :  -
Guru Occurances    :  -

 

                 
 
Company Profile   Athira Pharma is a late clinical-stage biopharmaceutical company. Co.'s primary candidate, fosgonimeton (ATH-1017), is a blood brain barrier-penetrating, small molecule hepatocyte growth factor (HGF)/MET positive modulator. The primary target indication is Alzheimer's disease (AD). Co.'s product candidate for its neuropsychiatric program is ATH-1020, which is a small molecule compound designed to be an orally available once-daily treatment, to enhance the HGF/MET system, and to distribute to the central nervous system. Co. has several preclinical candidates for non-AD indications, including ATH-1019, which is being developed to address peripheral indications such as peripheral neuropathy.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 605,686 685,698 2,157,060
Total Buy Value $0 $1,462,896 $1,705,913 $6,104,477
Total People Bought 0 1 2 6
Total Buy Transactions 0 3 6 13
Total Shares Sold 0 13,264 13,264 36,879
Total Sell Value $0 $38,598 $38,598 $102,919
Total People Sold 0 5 5 6
Total Sell Transactions 0 5 5 12
End Date 2024-01-28 2023-10-27 2023-04-28 2022-04-28

   
Records found: 53
  Page 2 of 3  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Mileson Glenna Chief Financial Officer   •       –      –    2022-06-22 4 A $0.00 $0 D/D 10,000 111,781     -
   Lenington Rachel Chief Operating Officer   •       –      –    2022-06-22 4 A $0.00 $0 D/D 10,000 10,000     -
   Worthington Mark General Counsel   •       –      –    2022-06-22 4 A $0.00 $0 D/D 10,000 21,711     -
   Church Kevin Executive VP, Research   •       –      –    2022-06-08 4 OE $1.35 $3,375 D/D 2,500 50,309     -
   Moebius Hans Chief Medical Officer   •       –      –    2022-05-18 4 A $7.06 $11,995 D/D 1,699 32,955     -
   Litton Mark James Chief Executive Officer   •       •      –    2022-05-18 4 A $7.06 $5,344 D/D 757 116,515     -
   Mileson Glenna Chief Financial Officer   •       –      –    2022-05-18 4 A $7.06 $12,150 D/D 1,721 101,781     -
   Worthington Mark General Counsel   •       –      –    2022-05-18 4 A $7.06 $23,976 D/D 3,396 11,711     -
   Church Kevin Executive VP, Research   •       –      –    2022-05-18 4 A $7.06 $1,716 D/D 243 47,809     -
   Mileson Glenna Chief Financial Officer   •       –      –    2022-04-11 4 OE $10.64 $31,920 D/D 3,000 100,060     -
   Romano Kelly A Director   –       •      –    2022-03-31 4 B $13.11 $104,880 D/D 8,000 8,315 2.39     -
   Pickering Grant Director   –       •      –    2022-03-21 3/A IO $0.00 $0 D/D 0 783     -
   Church Kevin Executive VP, Research   •       –      –    2022-02-18 4 OE $1.19 $3,751 D/D 3,152 47,566     -
   Mileson Glenna Chief Financial Officer   •       –      –    2022-01-04 4 OE $1.35 $8,512 D/D 6,305 97,060     -
   Litton Mark James Chief Executive Officer   •       •      –    2021-11-18 4 A $12.51 $11,071 D/D 885 115,758     -
   Moebius Hans Chief Medical Officer   •       –      –    2021-11-18 4 A $12.51 $10,371 D/D 829 31,256     -
   Church Kevin Executive VP, Research   •       –      –    2021-11-18 4 A $12.51 $1,201 D/D 96 44,414     -
   Mileson Glenna Chief Financial Officer   •       –      –    2021-11-18 4 A $12.51 $11,647 D/D 931 90,755     -
   Litton Mark James Chief Operating Officer   •       –      –    2021-08-17 4 OE $1.35 $68,094 D/D 50,440 114,873     -
   Moebius Hans Chief Medical Officer   •       –      –    2021-07-21 4 OE $1.35 $38,302 D/D 28,372 30,427     -
   Mileson Glenna Chief Financial Officer   •       –      –    2021-06-10 4 OE $1.35 $8,512 D/D 6,305 89,824     -
   Church Kevin Vice President of Discovery   •       –      –    2021-06-08 4/A OE $1.04 $3,278 D/D 3,152 44,318     -
   Church Kevin Vice President of Discovery   •       –      –    2021-06-08 4 OE $1.04 $3,278 D/D 3,152 44,133     -
   Worthington Mark General CounselOfficer   •       –      –    2021-06-01 3 IO $0.00 $0 D/D 0 8,315     -
   Litton Mark James Chief Operating Officer   •       –      –    2021-05-18 4 A $14.45 $12,528 D/D 867 64,433     -
  53 Records found
  1  2  3   
  Page 2 of 3
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us